Charmacy Pharmaceutical Co., Ltd.
Sümbol: 2289.HK
HKSE
10.6
HKDTuruhind täna
26.6977
P/E suhe
-2.4737
PEG suhe
1.14B
MRK Cap
- 0.07%
DIV tootlus
Charmacy Pharmaceutical Co., Ltd. (2289-HK) Finantsaruanded
Bilanss
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2048.73 | 634.2 | 503.8 | 641.8 | |||||||||||
balance-sheet.row.short-term-investments | 33.27 | 0 | 11.1 | 11.6 | |||||||||||
balance-sheet.row.net-receivables | 3455.49 | 965.4 | 865.3 | 731.3 | |||||||||||
balance-sheet.row.inventory | 2642.09 | 775.8 | 586.9 | 509.2 | |||||||||||
balance-sheet.row.other-current-assets | 1683.13 | 436.6 | 506.4 | 356 | |||||||||||
balance-sheet.row.total-current-assets | 9829.44 | 2812 | 2462.4 | 2238.2 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 1267.58 | 328.5 | 294.1 | 348.4 | |||||||||||
balance-sheet.row.goodwill | 24.1 | 6 | 6 | 6 | |||||||||||
balance-sheet.row.intangible-assets | 376.24 | 76.7 | 80.9 | 143 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 400.34 | 82.7 | 86.9 | 149.1 | |||||||||||
balance-sheet.row.long-term-investments | 1234.74 | 0 | 374.7 | 489.3 | |||||||||||
balance-sheet.row.tax-assets | 29.25 | 7.4 | 6.2 | 8.2 | |||||||||||
balance-sheet.row.other-non-current-assets | -1239.64 | 17 | -381 | -497.5 | |||||||||||
balance-sheet.row.total-non-current-assets | 1692.27 | 435.7 | 381 | 497.5 | |||||||||||
balance-sheet.row.other-assets | 71.28 | 0 | 22.6 | 27.4 | |||||||||||
balance-sheet.row.total-assets | 11593 | 3247.7 | 2865.9 | 2763.1 | |||||||||||
balance-sheet.row.account-payables | 3709.65 | 659.1 | 876.8 | 809.8 | |||||||||||
balance-sheet.row.short-term-debt | 5654.1 | 1531.1 | 1390 | 1512.6 | |||||||||||
balance-sheet.row.tax-payables | 296.21 | 56 | 94.2 | 44.6 | |||||||||||
balance-sheet.row.long-term-debt-total | 131.02 | 30.4 | 15.8 | 86.9 | |||||||||||
Deferred Revenue Non Current | -1.37 | -0.6 | 0 | 0.3 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1.52 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 3492.36 | 2.5 | 1378.8 | 1349.2 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 132.52 | 31 | 15.8 | 86.9 | |||||||||||
balance-sheet.row.other-liabilities | 11.38 | 0 | 0 | 13.2 | |||||||||||
balance-sheet.row.capital-lease-obligations | 84.83 | 37 | 15.8 | 15.5 | |||||||||||
balance-sheet.row.total-liab | 9303.15 | 2649.8 | 2271.4 | 2259 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 432 | 108 | 108 | 108 | |||||||||||
balance-sheet.row.retained-earnings | 712.22 | 181.2 | 207.5 | 117.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 280.97 | 279 | 1 | 1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 864.66 | 29.7 | 278 | 278 | |||||||||||
balance-sheet.row.total-stockholders-equity | 2289.85 | 597.8 | 594.5 | 504.1 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 11593 | 3247.7 | 2865.9 | 2763.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 2289.85 | 597.8 | 594.5 | 504.1 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 11593 | - | - | - | |||||||||||
Total Investments | 33.27 | 0 | 11.1 | 11.6 | |||||||||||
balance-sheet.row.total-debt | 5796.4 | 1561.5 | 1405.8 | 1611.9 | |||||||||||
balance-sheet.row.net-debt | 3780.94 | 927.3 | 913.1 | 981.8 |
Rahavoogude aruanne
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 141.73 | 90.4 | 23.2 | 40.6 | ||||||||||
cash-flows.row.depreciation-and-amortization | 41.75 | 28.8 | 32 | 24.6 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.change-in-working-capital | -404.55 | -300.2 | 20.9 | -227.9 | ||||||||||
cash-flows.row.account-receivables | -187.1 | -222.5 | -54.8 | -158 | ||||||||||
cash-flows.row.inventory | -217.45 | -77.7 | 75.8 | -69.8 | ||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-non-cash-items | 36.34 | 225 | -95.7 | 293.8 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -184.73 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -38.77 | -8.6 | -25 | -52 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | -2.9 | ||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-investing-activites | 160.41 | 80.4 | 0.6 | 0.1 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 121.65 | 71.8 | -24.4 | -54.8 | ||||||||||
cash-flows.row.debt-repayment | 0 | -1074.5 | -824.1 | -888.6 | ||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | -40.42 | -28.4 | -52.5 | -56.5 | ||||||||||
cash-flows.row.other-financing-activites | 52.15 | 911.7 | 951 | 942.5 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 11.73 | -191.2 | 74.4 | -2.7 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.05 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -51.31 | -75.4 | 30.5 | 73.6 | ||||||||||
cash-flows.row.cash-at-end-of-period | 332.42 | 68.9 | 144.2 | 113.8 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 383.73 | 144.2 | 113.8 | 40.1 | ||||||||||
cash-flows.row.operating-cash-flow | -184.73 | 44.1 | -19.5 | 131.1 | ||||||||||
cash-flows.row.capital-expenditure | -38.77 | -8.6 | -25 | -52 | ||||||||||
cash-flows.row.free-cash-flow | -223.5 | 35.5 | -44.6 | 79.1 |
Kasumiaruande rida
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 8578.91 | 4403.6 | 4175.3 | 3793.6 | |||||||||||
income-statement-row.row.cost-of-revenue | 8017.56 | 4110.9 | 3906.7 | 3559.5 | |||||||||||
income-statement-row.row.gross-profit | 561.35 | 292.7 | 268.6 | 234.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 97.18 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 235.39 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | -0.1 | -0.4 | -0.1 | |||||||||||
income-statement-row.row.operating-expenses | 304.92 | 178 | 116.1 | 163.4 | |||||||||||
income-statement-row.row.cost-and-expenses | 8322.48 | 4288.9 | 4022.8 | 3722.9 | |||||||||||
income-statement-row.row.interest-income | 66.96 | 4.3 | 30.5 | 37.7 | |||||||||||
income-statement-row.row.interest-expense | 0 | 40.8 | 35.1 | 41.5 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 235.39 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -12.61 | -41.2 | 28.6 | -41.4 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | -0.1 | -0.4 | -0.1 | |||||||||||
income-statement-row.row.total-operating-expenses | -12.61 | -41.2 | 28.6 | -41.4 | |||||||||||
income-statement-row.row.interest-expense | 0 | 40.8 | 35.1 | 41.5 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 53.79 | 26.5 | 25.7 | 29.1 | |||||||||||
income-statement-row.row.ebitda-caps | 255.88 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 202.09 | 66.2 | 93.5 | 74.4 | |||||||||||
income-statement-row.row.income-before-tax | 189.47 | 67.4 | 122.1 | 33 | |||||||||||
income-statement-row.row.income-tax-expense | 47.75 | 16.1 | 31.7 | 9.8 | |||||||||||
income-statement-row.row.net-income | 141.73 | 51.3 | 90.5 | 23.2 |
Korduma kippuv küsimus
Mis on Charmacy Pharmaceutical Co., Ltd. (2289.HK) koguvara?
Charmacy Pharmaceutical Co., Ltd. (2289.HK) koguvara on 3247655876.000.
Mis on ettevõtte aastane tulu?
Aastane tulu on 4403633477.000.
Mis on ettevõtte kasumimarginaal?
Ettevõtte kasumimarginaal on 0.066.
Mis on ettevõtte vaba rahavoog?
Vaba rahavoog on -2.398.
Mis on ettevõtte puhaskasumimarginaal?
Puhaskasumimarginaal on 0.012.
Mis on ettevõtte kogutulu?
Kogutulu on 0.025.
Mis on Charmacy Pharmaceutical Co., Ltd. (2289.HK) puhaskasum (puhaskasum)?
Puhaskasum (netotulu) on 51344725.000.
Kui suur on ettevõtte koguvõlg?
Koguvõlg on 1561459369.000.
Mis on tegevuskulude arv?
Tegevuskulud on 178011533.000.
Milline on ettevõtte rahaline näitaja?
Ettevõtte raha on 634197229.000.